The Peer’s lab works at the interface of materials science, chemistry, molecular biology, and immunology, to discover and validate novel therapeutic targets at the molecular level, and to develop specific genetic medicines for therapeutics and disease management.
The lab is highly dynamic, multidisciplinary, and focuses on developing targeted vehicles for cell-specific delivery of novel molecular medicines using RNAi , mRNA, saRNA, cirRNA, DNA, and novel genome editing strategies. The lab goal is to translate academic discoveries into innovative therapeutic modalities. With that in mind, Prof. Peer also founded SPARK Tel Aviv to accelerate cures via academic discoveries. Prof. Peer strives to develop the career of young students and encourage them to fulfill their ambitions and dreams.
Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform’s effectiveness
RNA therapeutics is an emerging field explored in various types of diseases such as genetic disorders, cancer, inflammation and viral infections. Currently, most of the
We use a conformation-sensitive targeting strategy to achieve in vivo gene silencing in a selective subset of leukocytes and show potential therapeutic applications in a
Genome editing approaches such as CRISPR/Cas9 system is routinely used to permanently and precisely disrupt potentially any gene of interest. Yet the efficiency of gene
RNA vaccines work by introducing an mRNA sequence, which is coded for a disease-specific antigen. This antigen is recognized by the immune system and starts
We are harnessing RNA payloads (RNAi, mRNA, saRNA, and cirRNA) as in vivo tools for drug discovery. Nucleic acids loaded lipid nanoparticles have emerged as a promising
Purim, March 2022 and Lab trip, May 2021
The Peer lab is designing novel methodologies to manipulate cells’ function in vivo, using targeted, safe, lipid nanoparticles. They are utilizing nanotechnology tools to generate novel therapeutic strategies for inflammatory diseases and cancers. The lab is combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery. In addition, they are designing highly selective targeted nanocarriers able to reprogram cells in a discerning manner, with an ultimate goal to translate the findings into clinical settings.
Srinivas Ramishetti*, Ranit Kedmi*, Meir Goldsmith, Fransisca Leonard, Andrew G. Sprague, Biana Godin, Michael Gozin, Pieter R. Cullis, Derek M. Dykxhoorn, and Dan Peer
Ranit Kedmi*, Nuphar Veiga*, Srinivas Ramishetti, Meir Goldsmith, Daniel Rosenblum,
Niels Dammes, Inbal Hazan-Halevy, Limor Nahary, Shani Leviatan-Ben-Arye, Michael Harlev,
Mark Behlke, Itai Benhar, Judy Lieberman and Dan Peer
Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti & Dan Peer